GSK, Pfizer, Others Targeted In DNA Patent Suit
Australia-based Genetic Technologies Ltd. has filed several suits over its technology since February 2010 and said in a statement that it had so far secured $14.5 million in licensing fees as a result.
Genetic Technologies CEO Paul MacLeman said in a statement that the suit will "further build on our strategy of systematizing [Genetic Technologies’] existing...
Already a subscriber? Click here to login